Healing & repair

ARA-290

Controlled trials

Unusually well studied for this category: cibinetide reached randomized placebo-controlled phase 2 trials in sarcoidosis-associated small fiber neuropathy and in type 2 diabetes, typically 2-4 mg subcutaneously once…

SubQAdvancedNot approved anywhereneuroprotectioninflammationimmune supportinjury repair

Also known as Cibinetide · Helix B Surface Peptide · pHBSP

At a glance

Dose summary

Typical dose4 mg
Range2 mg–4 mg
FrequencyDaily
Half-life~3 min
ScheduleOnce daily
Cycle length4 weeks
RouteSubQ
Experience levelAdvanced
Evidence gradeControlled trials
ApprovalNot approved anywhere
Where the dose comes fromPublished trial dosing

Reconstitution

What to draw, at the usual vial

A 5 mg vial reconstituted with 2 mL of bacteriostatic water gives 2.50 mg/mL. A typical 4 mg dose is 1.600 mL — pull the plunger to 160 units on a U-100 syringe.

Concentration2.50 mg/mL
Draw volume1.600 mL
U-100 units160 units
Doses per vial1

That will not fit one syringe

160 units is more than a 1 mL U-100 barrel holds. At this vial and this diluent volume the typical dose has to be split across two draws, or the vial mixed with less water to concentrate it. Work the alternative out on the calculator before you mix anything.

Same dose, other vial sizes

VialWaterConcentrationDrawUnitsDoses
2 mg2 mL1.00 mg/mLunder one dose
5 mg2 mL2.50 mg/mL1.600 mL160 units1

The highlighted row is the one quoted above: the largest listed vial, because no size here holds four typical doses. Change any of it — a different vial, more or less water, a different dose — on the reconstitution calculator, which draws the syringe to true U-100 graduations.

Mechanism & evidence

What it is, and what is known

Unusually well studied for this category: cibinetide reached randomized placebo-controlled phase 2 trials in sarcoidosis-associated small fiber neuropathy and in type 2 diabetes, typically 2-4 mg subcutaneously once daily for 28 days. Results were mixed and it is not approved anywhere. It is an EPO-derived peptide engineered not to stimulate erythropoiesis, so it does not raise haematocrit. Plasma half-life is only a few minutes; the effect is receptor-mediated and outlasts the exposure.

The caveat

Randomized placebo-controlled phase 2 work, but the results were mixed.

Tolerability

Reported side effects

  • Injection site reaction
  • Headache
  • Transient fatigue

Hard stops

Do not use this if

  • Pregnancy, possible pregnancy, or breastfeeding
  • Active, suspected or recently treated malignancy

These are flags, not a screening. They do not replace a conversation with a clinician who knows your history.

Handling

Storage

Sealed powder, refrigerated24 months
After reconstitution, refrigerated30 days

Keep it cold, keep it dark, and label the vial with the date you mixed it. Discard anything cloudy or past the window above.

Combinations

Commonly stacked with

Stacking multiplies the side-effect surface and makes it impossible to tell which compound did what. Add one thing at a time.

References

Sources

Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.